KALA · KALA BIO, Inc. · Executive Compensation
Market Cap
$9.20M
Shares
19.34M
Volume · Oct 2
1.08M
Avg daily vol (3M)
1.43M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Todd Bazemore | Former Interim Chief Executive Officer, President and Chief Operating Officer | $3,476,972 |
| Kim Brazzell | Former Head of Research and Development and Chief Medical Officer | $1,358,174 |
| Mary Reumuth | Former Chief Financial Officer | $1,322,608 |
| Mark Iwicki | Former Chief Executive Officer | $906,642 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Former Chief Executive Officer | $1,491,187 |
| Todd Bazemore | Former Interim Chief Executive Officer, President and Chief Operating Officer | $949,550 |
| Kim Brazzell | Former Head of Research and Development and Chief Medical Officer | $920,687 |
| Mary Reumuth | Former Chief Financial Officer | $778,269 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Former Chief Executive Officer | $8,342,714 |
| Todd Bazemore | Former Interim Chief Executive Officer, Former President and Chief Operating Officer | $2,943,656 |
| Kim Brazzell | Head of Research and Development and Chief Medical Officer | $2,923,073 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Chief Executive Officer | $1,868,299 |
| Todd Bazemore | President and Chief Operating Officer | $1,025,817 |
| Kim Brazzell | Head of Research and Development and Chief Medical Officer | $993,689 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mark Iwicki | Chief Executive Officer | $2,772,056 |
| Todd Bazemore | President and Chief Operating Officer | $1,343,356 |
| Kim Brazzell | Head of Research and Development and Chief Medical Officer | $1,316,969 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David Lazar | member of the Board of Directors | Resigned | 2026-02-20 |
| Avi Minkowitz | Chief Financial Officer | Appointed | 2026-02-05 |
| Avi Minkowitz | Chief Executive Officer | Appointed | 2026-02-05 |
| David Lazar | Chief Financial Officer | Resigned | 2026-02-05 |
| David Lazar | Chief Executive Officer | Resigned | 2026-02-05 |
| David Lazar | Class II director | Appointed | 2026-02-02 |
| Howard B. Rosen | Class III director | Resigned | 2026-02-02 |
| C. Daniel Meyers | Class III director | Resigned | 2026-02-02 |
| Mark Iwicki | Class II director | Resigned | 2026-02-02 |
| Todd Bazemore | Class II director | Resigned | 2026-02-02 |
| Andrew I. Koven | Class I director | Resigned | 2026-02-02 |
| Marjan Farid | Class I director | Resigned | 2026-02-02 |
| Howard B. Rosen | director | Resigned | 2025-12-29 |
| Todd Bazmore | director | Resigned | 2025-12-29 |
| C. Daniel Myers | director | Resigned | 2025-12-29 |
| Mark Iwicki | director | Resigned | 2025-12-29 |
| Andrew I. Koven | director | Resigned | 2025-12-29 |
| Marjan Farid, M.D. | director | Resigned | 2025-12-29 |
| David Lazar | Chairman of the Board of Directors | Appointed | 2025-11-25 |
| David Lazar | Board of Directors | Appointed | 2025-11-25 |
| Todd Bazemore | President and Chief Executive Officer | Terminated | 2025-10-20 |
| Todd Bazemore | Class II director | Appointed | 2025-09-02 |
| Todd Bazemore | Chief Executive Officer | Appointed | 2025-09-02 |
| Todd Bazemore | interim Chief Executive Officer and principal executive officer | Appointed | 2025-02-12 |
| Mark Iwicki | Chief Executive Officer | Resigned | 2025-02-12 |